| 1.63 0.02 (1.24%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.23 |
1-year : | 2.51 |
| Resists | First : | 1.9 |
Second : | 2.15 |
| Pivot price | 1.81 |
|||
| Supports | First : | 1.51 |
Second : | 1.26 |
| MAs | MA(5) : | 1.67 |
MA(20) : | 1.86 |
| MA(100) : | 2.82 |
MA(250) : | 5.53 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2  |
| %K %D | K(14,3) : | 12.3 |
D(3) : | 8.3 |
| RSI | RSI(14): 32.7 |
|||
| 52-week | High : | 22.79 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BNGO ] has closed above bottom band by 10.1%. Bollinger Bands are 59.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.63 - 1.64 | 1.64 - 1.65 |
| Low: | 1.49 - 1.51 | 1.51 - 1.52 |
| Close: | 1.61 - 1.63 | 1.63 - 1.65 |
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Thu, 30 Oct 2025
Bionano Genomics (Nasdaq: BNGO) sets Nov. 13, 4:30 p.m. ET webcast to report results - Stock Titan
Sun, 21 Sep 2025
Bionano Genomics Launches $10 Million Public Offering - Yahoo Finance
Thu, 18 Sep 2025
BioNano Genomics Completes $9 Million Public Offering - TipRanks
Wed, 17 Sep 2025
Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering - GlobeNewswire
Tue, 16 Sep 2025
Bionano Genomics (BNGO) Announces $10M Public Offering - GuruFocus
Tue, 16 Sep 2025
$30M Total Potential: Bionano Genomics Launches Strategic Public Offering with 5-Year Warrants - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 10 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 14.7 (%) |
| Shares Short | 1,040 (K) |
| Shares Short P.Month | 706 (K) |
| EPS | -43.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.6 |
| Profit Margin | -271.1 % |
| Operating Margin | -115.9 % |
| Return on Assets (ttm) | -30.9 % |
| Return on Equity (ttm) | -118.3 % |
| Qtrly Rev. Growth | -13.4 % |
| Gross Profit (p.s.) | 0.14 |
| Sales Per Share | 2.83 |
| EBITDA (p.s.) | -3.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.14 |
| Price to Sales | 0.57 |
| Price to Cash Flow | -0.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|